- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Baxter signs consent decree with FDA
The FDA announced that Baxter Healthcare Corp. and two of its top corporate executives have signed a consent decree of condemnation and permanent injunction for certain infusion pumps made by the firm. They agreed to stop manufacturing and distributing within the United States all models of the Colleague Volumetric Infusion Pump (Colleague) and the Syndeo Patient Controlled Analgesic Syringe Pump (Syndeo) until they correct manufacturing deficiencies and until the devices are made in compliance with the FDA's current good manufacturing practice (CGMP) requirements and the Quality System (QS) regulation for devices.
Baxter signs consent decree with FDA
The FDA announced that Baxter Healthcare Corp. and two of its top corporate executives have signed a consent decree of condemnation and permanent injunction for certain infusion pumps made by the firm. They agreed to stop manufacturing and distributing within the United States all models of the Colleague Volumetric Infusion Pump (Colleague) and the Syndeo Patient Controlled Analgesic Syringe Pump (Syndeo) until they correct manufacturing deficiencies and until the devices are made in compliance with the FDA's current good manufacturing practice (CGMP) requirements and the Quality System (QS) regulation for devices. Under the terms of the consent decree, signed by Baxter's chairman, CEO, and other top executives, the company has agreed to take necessary measures to ensure compliance with the CGMP and QS requirements by all of its facilities that manufacture, process, pack, label, hold, or distribute the Colleague and Syndeo Pumps. The decree also requires Baxter to retain an independent expert consultant to conduct inspections of its infusion pump facilities and certify to the FDA that corrections have been made. The agency will continue to monitor these activities through its inspections.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
Stress Ulcer Prophylaxis May Not Prevent Gastrointestinal Bleeding in Neonates
December 4th 2023According to a poster presented at ASHP Midyear 2023, stress ulcer prophylaxis (SUP) did not increase adverse effects, suggesting limited preventive benefits for gastrointestinal bleeding (GIB) in neonates.
Instagram Could Serve as Educational Platform for New FDA Drug Approvals
December 4th 2023An evaluative study on an open resource Instagram page that provides information on new medications to pharmacists was recently presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition.
